Polaryx Therapeutics, Inc./$PLYX
1D1W1MYTD1Y5YMAX
About Polaryx Therapeutics, Inc.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
- Ticker
- $PLYX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Paramus, United States
- Website
- polaryx.com
PLYX Metrics
BasicAdvanced
$103M
-
-$0.15
-
-
Price and volume
Market cap
$103M
52-week high
$9.18
52-week low
$1.85
Average daily volume
114K
Financial strength
Current ratio
13.53
Quick ratio
13.221
Profitability
Management effectiveness
Return on assets (TTM)
-42.52%
Return on equity (TTM)
-96.56%
Valuation
Price to book
9.39
Price to tangible book (TTM)
9.39
Price to free cash flow (TTM)
-16.684
Free cash flow yield (TTM)
-5.99%
Free cash flow per share (TTM)
-0.123
Growth
Earnings per share change (TTM)
-19.84%
What the Analysts think about PLYX
Analyst ratings (Buy, Hold, Sell) for Polaryx Therapeutics, Inc. stock.
PLYX Financial Performance
Revenues and expenses
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.